1
|
Asadi F, Gunawardana SC, Dolle RE, Piston DW. An orally available compound suppresses glucagon hypersecretion and normalizes hyperglycemia in type 1 diabetes. JCI Insight 2024; 9:e172626. [PMID: 38258903 PMCID: PMC10906223 DOI: 10.1172/jci.insight.172626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Accepted: 12/05/2023] [Indexed: 01/24/2024] Open
Abstract
Suppression of glucagon hypersecretion can normalize hyperglycemia during type 1 diabetes (T1D). Activating erythropoietin-producing human hepatocellular receptor type-A4 (EphA4) on α cells reduced glucagon hypersecretion from dispersed α cells and T1D islets from both human donor and mouse models. We synthesized a high-affinity small molecule agonist for the EphA4 receptor, WCDD301, which showed robust plasma and liver microsome metabolic stability in both mouse and human preparations. In islets and dispersed islet cells from nondiabetic and T1D human donors, WCDD301 reduced glucagon secretion comparable to the natural EphA4 ligand, Ephrin-A5. In diabetic NOD and streptozotocin-treated mice, once-daily oral administration of WCDD301 formulated with a time-release excipient reduced plasma glucagon and normalized blood glucose for more than 3 months. These results suggest that targeting the α cell EphA4 receptor by sustained release of WCDD301 is a promising pharmacologic pathway for normalizing hyperglycemia in patients with T1D.
Collapse
Affiliation(s)
| | | | - Roland E. Dolle
- Center for Drug Discovery, Washington University School of Medicine, St. Louis, Missouri, USA
| | | |
Collapse
|
2
|
Lee SW, Oh YM, Victor MB, Yang Y, Chen S, Strunilin I, Dahiya S, Dolle RE, Pak SC, Silverman GA, Perlmutter DH, Yoo AS. Longitudinal modeling of human neuronal aging reveals the contribution of the RCAN1-TFEB pathway to Huntington's disease neurodegeneration. Nat Aging 2024; 4:95-109. [PMID: 38066314 DOI: 10.1038/s43587-023-00538-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Accepted: 11/03/2023] [Indexed: 12/19/2023]
Abstract
Aging is a common risk factor in neurodegenerative disorders. Investigating neuronal aging in an isogenic background stands to facilitate analysis of the interplay between neuronal aging and neurodegeneration. Here we perform direct neuronal reprogramming of longitudinally collected human fibroblasts to reveal genetic pathways altered at different ages. Comparative transcriptome analysis of longitudinally aged striatal medium spiny neurons (MSNs) in Huntington's disease identified pathways involving RCAN1, a negative regulator of calcineurin. Notably, RCAN1 protein increased with age in reprogrammed MSNs as well as in human postmortem striatum and RCAN1 knockdown rescued patient-derived MSNs of Huntington's disease from degeneration. RCAN1 knockdown enhanced chromatin accessibility of genes involved in longevity and autophagy, mediated through enhanced calcineurin activity, leading to TFEB's nuclear localization by dephosphorylation. Furthermore, G2-115, an analog of glibenclamide with autophagy-enhancing activities, reduced the RCAN1-calcineurin interaction, phenocopying the effect of RCAN1 knockdown. Our results demonstrate that targeting RCAN1 genetically or pharmacologically can increase neuronal resilience in Huntington's disease.
Collapse
Affiliation(s)
- Seong Won Lee
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Biomedical Sciences, Mercer University School of Medicine, Columbus, GA, USA
| | - Young Mi Oh
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
- Department of Biomedical Sciences, Mercer University School of Medicine, Columbus, GA, USA
| | - Matheus B Victor
- Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Yan Yang
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Shawei Chen
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Ilya Strunilin
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Sonika Dahiya
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| | - Roland E Dolle
- Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA
| | - Stephen C Pak
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Gary A Silverman
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - David H Perlmutter
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Andrew S Yoo
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA.
- Center of Regenerative Medicine, Washington University School of Medicine, St. Louis, MO, USA.
| |
Collapse
|
3
|
Murphy CK, Dixit B, Oleson FB, Dolle RE, Farquhar R, McCormick BA. Development of ADS051, an oral, gut-restricted, small molecule neutrophil modulator for the treatment of neutrophil-mediated inflammatory diseases. FEBS Open Bio 2023. [PMID: 37392453 PMCID: PMC10392058 DOI: 10.1002/2211-5463.13668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 06/05/2023] [Accepted: 06/23/2023] [Indexed: 07/03/2023] Open
Abstract
Neutrophils are an essential component of the innate immune system; however, uncontrolled neutrophil activity can lead to inflammation and tissue damage in acute and chronic diseases. Despite inclusion of neutrophil presence and activity in clinical evaluations of inflammatory diseases, the neutrophil has been an overlooked therapeutic target. The goal of this program was to design a small molecule regulator of neutrophil trafficking and activity that fulfilled the following criteria: (a) modulates neutrophil epithelial transmigration and activation, (b) lacks systemic exposure, (c) preserves protective host immunity, and (d) is administered orally. The result of this discovery program was ADS051 (also known as BT051), a low permeability, small molecule modulator of neutrophil trafficking and activity via blockade of multidrug resistance protein 2 (MRP2)- and formyl peptide receptor 1 (FPR1)-mediated mechanisms. ADS051, based on a modified scaffold derived from cyclosporine A (CsA), was designed to have reduced affinity for calcineurin with low cell permeability and, thus, a greatly reduced ability to inhibit T-cell function. In cell-based assays, ADS051 did not inhibit cytokine secretion from activated human T cells. Further, in preclinical models, ADS051 showed limited systemic absorption (<1% of total dose) after oral administration, and assessment of ADS051 in human, cell-based systems demonstrated inhibition of neutrophil epithelial transmigration. In addition, preclinical toxicology studies in rats and monkeys receiving daily oral doses of ADS051 for 28 days did not reveal safety risks or ADS051-related toxicity. Our results to date support the clinical development of ADS051 in patients with neutrophil-mediated inflammatory diseases.
Collapse
Affiliation(s)
- Christopher K Murphy
- Adiso Therapeutics, Inc. (formerly Bacainn Therapeutics, Inc.), Concord, MA, United States of America
| | - Bharat Dixit
- Adiso Therapeutics, Inc. (formerly Bacainn Therapeutics, Inc.), Concord, MA, United States of America
| | | | - Roland E Dolle
- Medicine Inventions, LLC, Eureka, MO, United States of America
| | - Ronald Farquhar
- Adiso Therapeutics, Inc. (formerly Bacainn Therapeutics, Inc.), Concord, MA, United States of America
- Resolvix Bio, Inc, Battery Wharf, Boston, MA, United States of America
| | - Beth A McCormick
- Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA, United States of America
- Program in Microbiome Dynamics, University of Massachusetts Chan Medical School, Worcester, MA, United States of America
| |
Collapse
|
4
|
Docherty CAH, Fernando AJ, Rosli S, Lam M, Dolle RE, Navia MA, Farquhar R, La France D, Tate MD, Murphy CK, Rossi AG, Mansell A. A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. Clin Transl Immunology 2023; 12:e1455. [PMID: 37360982 PMCID: PMC10288073 DOI: 10.1002/cti2.1455] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 05/14/2023] [Accepted: 06/06/2023] [Indexed: 06/28/2023] Open
Abstract
Objectives Inflammasomes induce maturation of the inflammatory cytokines IL-1β and IL-18, whose activity is associated with the pathophysiology of a wide range of infectious and inflammatory diseases. As validated therapeutic targets for the treatment of acute and chronic inflammatory diseases, there has been intense interest in developing small-molecule inhibitors to target inflammasome activity and reduce disease-associated inflammatory burden. Methods We examined the therapeutic potential of a novel small-molecule inhibitor, and associated derivatives, termed ADS032 to target and reduce inflammasome-mediated inflammation in vivo. In vitro, we characterised ADS032 function, target engagement and specificity. Results We describe ADS032 as the first dual NLRP1 and NLRP3 inhibitor. ADS032 is a rapid, reversible and stable inflammasome inhibitor that directly binds both NLRP1 and NLRP3, reducing secretion and maturation of IL-1β in human-derived macrophages and bronchial epithelial cells in response to the activation of NLPR1 and NLRP3. ADS032 also reduced NLRP3-induced ASC speck formation, indicative of targeting inflammasome formation. In vivo, ADS032 reduced IL-1β and TNF-α levels in the serum of mice challenged i.p. with LPS and reduced pulmonary inflammation in an acute model of lung silicosis. Critically, ADS032 protected mice from lethal influenza A virus challenge, displayed increased survival and reduced pulmonary inflammation. Conclusion ADS032 is the first described dual inflammasome inhibitor and a potential therapeutic to treat both NLRP1- and NLRP3-associated inflammatory diseases and also constitutes a novel tool that allows examination of the role of NLRP1 in human disease.
Collapse
Affiliation(s)
- Callum AH Docherty
- Centre for Innate Immunity and Infectious DiseasesHudson Institute of Medical ResearchClaytonVICAustralia
- Department of Molecular and Translational SciencesMonash UniversityClaytonVICAustralia
| | - Anuruddika J Fernando
- University of Edinburgh Centre for Inflammation ResearchQueen's Medical Research Institute, Edinburgh BioQuarterEdinburghUK
| | - Sarah Rosli
- Centre for Innate Immunity and Infectious DiseasesHudson Institute of Medical ResearchClaytonVICAustralia
- Department of Molecular and Translational SciencesMonash UniversityClaytonVICAustralia
| | - Maggie Lam
- Centre for Innate Immunity and Infectious DiseasesHudson Institute of Medical ResearchClaytonVICAustralia
- Department of Molecular and Translational SciencesMonash UniversityClaytonVICAustralia
| | - Roland E Dolle
- Department of Biochemistry and Molecular BiophysicsWashington University School of MedicineSt. LouisMOUSA
| | | | | | | | - Michelle D Tate
- Centre for Innate Immunity and Infectious DiseasesHudson Institute of Medical ResearchClaytonVICAustralia
- Department of Molecular and Translational SciencesMonash UniversityClaytonVICAustralia
| | | | - Adriano G Rossi
- University of Edinburgh Centre for Inflammation ResearchQueen's Medical Research Institute, Edinburgh BioQuarterEdinburghUK
| | - Ashley Mansell
- Centre for Innate Immunity and Infectious DiseasesHudson Institute of Medical ResearchClaytonVICAustralia
- Department of Molecular and Translational SciencesMonash UniversityClaytonVICAustralia
- Adiso TherapeuticsConcordMAUSA
| |
Collapse
|
5
|
Lee SW, Oh YM, Victor MB, Strunilin I, Chen S, Dahiya S, Dolle RE, Pak SC, Silverman GA, Perlmutter DH, Yoo AS. Longitudinal modeling of human neuronal aging identifies RCAN1-TFEB pathway contributing to neurodegeneration of Huntington's disease. Res Sq 2023:rs.3.rs-2815300. [PMID: 37214956 PMCID: PMC10197783 DOI: 10.21203/rs.3.rs-2815300/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Aging is a common risk factor in neurodegenerative disorders and the ability to investigate aging of neurons in an isogenic background would facilitate discovering the interplay between neuronal aging and onset of neurodegeneration. Here, we perform direct neuronal reprogramming of longitudinally collected human fibroblasts to reveal genetic pathways altered at different ages. Comparative transcriptome analysis of longitudinally aged striatal medium spiny neurons (MSNs), a primary neuronal subtype affected in Huntington's disease (HD), identified pathways associated with RCAN1, a negative regulator of calcineurin. Notably, RCAN1 undergoes age-dependent increase at the protein level detected in reprogrammed MSNs as well as in human postmortem striatum. In patient-derived MSNs of adult-onset HD (HD-MSNs), counteracting RCAN1 by gene knockdown (KD) rescued HD-MSNs from degeneration. The protective effect of RCAN1 KD was associated with enhanced chromatin accessibility of genes involved in longevity and autophagy, mediated through enhanced calcineurin activity, which in turn dephosphorylates and promotes nuclear localization of TFEB transcription factor. Furthermore, we reveal that G2-115 compound, an analog of glibenclamide with autophagy-enhancing activities, reduces the RCAN1-Calcineurin interaction, phenocopying the effect of RCAN1 KD. Our results demonstrate that RCAN1 is a potential genetic or pharmacological target whose reduction-of-function increases neuronal resilience to neurodegeneration in HD through chromatin reconfiguration.
Collapse
Affiliation(s)
- Seong Won Lee
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Young Mi Oh
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Matheus B Victor
- Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Ilya Strunilin
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Shawei Chen
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Sonika Dahiya
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110
| | - Roland E Dolle
- Department of Biochemistry, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Stephen C Pak
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Gary A Silverman
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - David H Perlmutter
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - Andrew S Yoo
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
- Center of Regenerative Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
| |
Collapse
|
6
|
Oh YM, Lee SW, Kim WK, Chen S, Church VA, Cates K, Li T, Zhang B, Dolle RE, Dahiya S, Pak SC, Silverman GA, Perlmutter DH, Yoo AS. Age-related Huntington's disease progression modeled in directly reprogrammed patient-derived striatal neurons highlights impaired autophagy. Nat Neurosci 2022; 25:1420-1433. [PMID: 36303071 PMCID: PMC10162007 DOI: 10.1038/s41593-022-01185-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 09/19/2022] [Indexed: 01/13/2023]
Abstract
Huntington's disease (HD) is an inherited neurodegenerative disorder with adult-onset clinical symptoms, but the mechanism by which aging drives the onset of neurodegeneration in patients with HD remains unclear. In this study we examined striatal medium spiny neurons (MSNs) directly reprogrammed from fibroblasts of patients with HD to model the age-dependent onset of pathology. We found that pronounced neuronal death occurred selectively in reprogrammed MSNs from symptomatic patients with HD (HD-MSNs) compared to MSNs derived from younger, pre-symptomatic patients (pre-HD-MSNs) and control MSNs from age-matched healthy individuals. We observed age-associated alterations in chromatin accessibility between HD-MSNs and pre-HD-MSNs and identified miR-29b-3p, whose age-associated upregulation promotes HD-MSN degeneration by impairing autophagic function through human-specific targeting of the STAT3 3' untranslated region. Reducing miR-29b-3p or chemically promoting autophagy increased the resilience of HD-MSNs against neurodegeneration. Our results demonstrate miRNA upregulation with aging in HD as a detrimental process driving MSN degeneration and potential approaches for enhancing autophagy and resilience of HD-MSNs.
Collapse
Affiliation(s)
- Young Mi Oh
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Seong Won Lee
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Woo Kyung Kim
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Shawei Chen
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Victoria A Church
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Kitra Cates
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
| | - Tiandao Li
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
- Center of Regenerative Medicine, Washington University School of Medicine, St. Louis, MO, USA
| | - Bo Zhang
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
- Center of Regenerative Medicine, Washington University School of Medicine, St. Louis, MO, USA
| | - Roland E Dolle
- Department of Biochemistry, Washington University School of Medicine, St. Louis, MO, USA
| | - Sonika Dahiya
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| | - Stephen C Pak
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Gary A Silverman
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - David H Perlmutter
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
| | - Andrew S Yoo
- Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA.
- Center of Regenerative Medicine, Washington University School of Medicine, St. Louis, MO, USA.
| |
Collapse
|
7
|
Dang X, Zhang L, Franco A, Li J, Rocha AG, Devanathan S, Dolle RE, Bernstein PR, Dorn GW. Correction to “Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases”. J Med Chem 2020; 63:10086. [DOI: 10.1021/acs.jmedchem.0c01267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Dang X, Zhang L, Franco A, Li J, Rocha AG, Devanathan S, Dolle RE, Bernstein PR, Dorn GW. Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases. J Med Chem 2020; 63:7033-7051. [PMID: 32506913 DOI: 10.1021/acs.jmedchem.0c00366] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Mutations in the mitochondrial fusion protein mitofusin (MFN) 2 cause the chronic neurodegenerative condition Charcot-Marie-Tooth disease type 2A (CMT2A), for which there is currently no treatment. Small-molecule activators of MFN1 and MFN2 enhance mitochondrial fusion and offer promise as therapy for this condition, but prototype compounds have poor pharmacokinetic properties. Herein, we describe a rational design of a series of 6-phenylhexanamide derivatives whose pharmacokinetic optimization yielded a 4-hydroxycyclohexyl analogue, 13, with the potency, selectivity, and oral bioavailability of a preclinical candidate. Studies of 13 cis- and trans-4-hydroxycyclohexyl isostereomers unexpectedly revealed functionality and protein engagement exclusively for the trans form, 13B. Preclinical absorption, distribution, metabolism, and excretion (ADME) and in vivo target engagement studies of 13B support further development of 6-phenylhexanamide derivatives as therapeutic agents for human CMT2A.
Collapse
Affiliation(s)
- Xiawei Dang
- Department of Cardiology, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710061, Shaanxi, China.,Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States
| | - Lihong Zhang
- Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States
| | - Antonietta Franco
- Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States.,Mitochondria in Motion, Inc. 4340 Duncan Avenue, Suite 216, St. Louis, Missouri 63110, United States
| | - Jiajia Li
- Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States
| | - Agostinho G Rocha
- Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States
| | - Sriram Devanathan
- Mitochondria in Motion, Inc. 4340 Duncan Avenue, Suite 216, St. Louis, Missouri 63110, United States
| | - Roland E Dolle
- Mitochondria in Motion, Inc. 4340 Duncan Avenue, Suite 216, St. Louis, Missouri 63110, United States.,Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 S. Euclid Ave. St. Louis, Missouri 63110, United States
| | - Peter R Bernstein
- Harrington Discovery Institute at University Hospitals, 11407 Euclid Ave, Cleveland, Ohio 44106, United States
| | - Gerald W Dorn
- Center for Pharmacogenomics, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States.,Mitochondria in Motion, Inc. 4340 Duncan Avenue, Suite 216, St. Louis, Missouri 63110, United States
| |
Collapse
|
9
|
Cross JB, Zhang J, Yang Q, Mesleh MF, Romero JAC, Wang B, Bevan D, Poutsiaka KM, Epie F, Moy T, Daniel A, Shotwell J, Chamberlain B, Carter N, Andersen O, Barker J, Ryan MD, Metcalf CA, Silverman J, Nguyen K, Lippa B, Dolle RE. Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design. ACS Med Chem Lett 2016; 7:374-8. [PMID: 27096044 DOI: 10.1021/acsmedchemlett.5b00368] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2015] [Accepted: 02/06/2016] [Indexed: 12/20/2022] Open
Abstract
The ATPase subunit of DNA gyrase B is an attractive antibacterial target due to high conservation across bacteria and the essential role it plays in DNA replication. A novel class of pyrazolopyridone inhibitors was discovered by optimizing a fragment screening hit scaffold using structure guided design. These inhibitors show potent Gram-positive antibacterial activity and low resistance incidence against clinically important pathogens.
Collapse
Affiliation(s)
- Jason B. Cross
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Jing Zhang
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Qingyi Yang
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Michael F. Mesleh
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | | | - Bin Wang
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Doug Bevan
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Katherine M. Poutsiaka
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Felix Epie
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Terence Moy
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Anu Daniel
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Joseph Shotwell
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Brian Chamberlain
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Nicole Carter
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Ole Andersen
- Evotec U.K., Ltd., 114 Innovation
Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom
| | - John Barker
- Evotec U.K., Ltd., 114 Innovation
Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, United Kingdom
| | - M. Dominic Ryan
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Chester A. Metcalf
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Jared Silverman
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Kien Nguyen
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Blaise Lippa
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| | - Roland E. Dolle
- Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
| |
Collapse
|
10
|
Zhang J, Yang Q, Cross JB, Romero JAC, Poutsiaka KM, Epie F, Bevan D, Wang B, Zhang Y, Chavan A, Zhang X, Moy T, Daniel A, Nguyen K, Chamberlain B, Carter N, Shotwell J, Silverman J, Metcalf CA, Ryan D, Lippa B, Dolle RE. Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors. J Med Chem 2015; 58:8503-12. [DOI: 10.1021/acs.jmedchem.5b00961] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Jing Zhang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Qingyi Yang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Jason B. Cross
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | | | | | - Felix Epie
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Douglas Bevan
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Bin Wang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Yanzhi Zhang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Ajit Chavan
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Xin Zhang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Terence Moy
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Anu Daniel
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Kien Nguyen
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Brian Chamberlain
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Nicole Carter
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Joseph Shotwell
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Jared Silverman
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Chester A. Metcalf
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Dominic Ryan
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Blaise Lippa
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Roland E. Dolle
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| |
Collapse
|
11
|
Zhang J, Yang Q, Romero JAC, Cross J, Wang B, Poutsiaka KM, Epie F, Bevan D, Wu Y, Moy T, Daniel A, Chamberlain B, Carter N, Shotwell J, Arya A, Kumar V, Silverman J, Nguyen K, Metcalf CA, Ryan D, Lippa B, Dolle RE. Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors. ACS Med Chem Lett 2015; 6:1080-5. [PMID: 26487916 DOI: 10.1021/acsmedchemlett.5b00266] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 09/08/2015] [Indexed: 11/28/2022] Open
Abstract
Antibacterials with a novel mechanism of action offer a great opportunity to combat widespread antimicrobial resistance. Bacterial DNA Gyrase is a clinically validated target. Through physiochemical property optimization of a pyrazolopyridone hit, a novel class of GyrB inhibitors were discovered. Guided by structure-based drug design, indazole derivatives with excellent enzymatic and antibacterial activity as well as great animal efficacy were discovered.
Collapse
Affiliation(s)
- Jing Zhang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Qingyi Yang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | | | - Jason Cross
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Bin Wang
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | | | - Felix Epie
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Douglas Bevan
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Yuchuan Wu
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Terence Moy
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Anu Daniel
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Brian Chamberlain
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Nicole Carter
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Joseph Shotwell
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Anu Arya
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Vipul Kumar
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Jared Silverman
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Kien Nguyen
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Chester A. Metcalf
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Dominic Ryan
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Blaise Lippa
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| | - Roland E. Dolle
- Cubist Pharmaceuticals Inc., Lexington, Massachusetts 02421, United States
| |
Collapse
|
12
|
Carroll FI, Dolle RE. The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists. ChemMedChem 2014; 9:1638-54. [PMID: 24981721 PMCID: PMC5588862 DOI: 10.1002/cmdc.201402142] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2014] [Indexed: 01/12/2023]
Abstract
N-Substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines are a class of pure opioid receptor antagonists with a novel pharmacophore. This opioid receptor antagonist pharmacophore was used as a lead structure to design and develop several interesting and useful opioid receptor antagonists. In this review we describe: 1) early SAR studies that led to the discovery of LY255582 and analogues that are nonselective opioid receptor antagonists developed for the treatment of obesity; 2) the discovery and commercialization of LY246736 (alvimopan; ENTEREG®), a peripherally selective opioid receptor antagonist that accelerates the time to upper and lower GI recovery following surgeries that include partial bowel resection with primary anastomosis; and 3) the discovery and development of the potent and selective κ opioid receptor antagonist JDTic and analogues as potential pharmacotherapies for treating depression, anxiety, and substance abuse (nicotine, alcohol, and cocaine). In addition, the use of JDTic for obtaining the X-ray structure of the human κ opioid receptor is discussed.
Collapse
Affiliation(s)
- F Ivy Carroll
- Research Triangle Institute, Center for Organic and Medicinal Chemistry, 3040 Cornwallis Road, Research Triangle Park, NC 27709 (USA).
| | | |
Collapse
|
13
|
Nozaki C, Le Bourdonnec B, Reiss D, Windh RT, Little PJ, Dolle RE, Kieffer BL, Gavériaux-Ruff C. δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther 2012; 342:799-807. [PMID: 22700431 DOI: 10.1124/jpet.111.188987] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5747) are novel δ-opioid agonists that show good oral bioavailability and analgesic and antidepressive effects in the rat and represent potential drugs for chronic pain treatment. Here, we used genetic approaches to investigate molecular mechanisms underlying their analgesic effects in the mouse. We tested analgesic effects of ADL5859 and ADL5747 in mice by using mechanical sensitivity measures in both complete Freund's adjuvant and sciatic nerve ligation pain models. We examined their analgesic effects in δ-opioid receptor constitutive knockout (KO) mice and mice with a conditional deletion of δ-receptor in peripheral voltage-gated sodium channel (Nav)1.8-expressing neurons (cKO mice). Both ADL5859 and ADL5747, and the prototypical δ agonist 4-[(R)-[(2S,5R)-4-allyl-2,5-dimethyl-piperazin-1-yl]-(3-methoxyphenyl)methyl]-N,N-diethyl-benzamide (SNC80) as a control, significantly reduced inflammatory and neuropathic pain. The antiallodynic effects of all three δ-opioid agonists were abolished in constitutive δ-receptor KO mice and strongly diminished in δ-receptor cKO mice. We also measured two other well described effects of δ agonists, increase in locomotor activity and agonist-induced receptor internalization by using knock-in mice expressing enhanced green fluorescence protein-tagged δ receptors. In contrast to SNC80, ADL5859 and ADL5747 did not induce either hyperlocomotion or receptor internalization in vivo. In conclusion, both ADL5859 and ADL5747 showed efficient pain-reducing properties in the two models of chronic pain. Their effects were mediated by δ-opioid receptors, with a main contribution of receptors expressed on peripheral Nav1.8-positive neurons. The lack of in vivo receptor internalization and locomotor activation, typically induced by SNC80, suggests agonist-biased activity at the receptor for the two drugs.
Collapse
Affiliation(s)
- Chihiro Nozaki
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France
| | | | | | | | | | | | | | | |
Collapse
|
14
|
LaBuda CJ, Koblish M, Tuthill P, Dolle RE, Little PJ. Antinociceptive activity of the selective iNOS inhibitor AR-C102222 in rodent models of inflammatory, neuropathic and post-operative pain. Eur J Pain 2012; 10:505-12. [PMID: 16125426 DOI: 10.1016/j.ejpain.2005.07.004] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2005] [Revised: 06/23/2005] [Accepted: 07/13/2005] [Indexed: 11/17/2022]
Abstract
Nitric oxide generated by the nitric oxide synthase (NOS) isoforms contributes to pain processing. The selective inhibition of iNOS might represent a novel, therapeutic target for the development of antinociceptive compounds. However, few isoform-selective inhibitors of NOS have been developed. The present experiments examined the anti-inflammatory and antinociceptive activity of a selective inducible nitric oxide (iNOS) inhibitor, AR-C102222, on arachidonic acid-induced ear inflammation, Freund's complete adjuvant (FCA)-induced hyperalgesia, acetic acid-induced writhing, and tactile allodynia produced by L5 spinal nerve ligation (L5 SNL) or hindpaw incision (INC). AR-C102222 at a dose of 100mg/kg p.o., significantly reduced inflammation produced by the application of arachidonic acid to the ear, attenuated FCA-induced mechanical hyperalgesia, and attenuated acetic acid-induced writhing. In the L5 SNL and INC surgical procedures, tactile allodynia produced by both procedures was significantly reduced by 30mg/kg i.p. of AR-C102222. These data demonstrate that the selective inhibition of iNOS produces antinociception in different models of pain and suggest that the iNOS-NO system plays a role in pain processing.
Collapse
|
15
|
Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM. The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease. Mov Disord 2011; 26:1225-33. [DOI: 10.1002/mds.23631] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Revised: 12/06/2010] [Accepted: 12/16/2010] [Indexed: 11/05/2022] Open
|
16
|
Abstract
High-throughput chemistry (HTC) is approaching its 20-year anniversary. Since 1992, some 5,000 chemical libraries, prepared for the purpose of biological investigation and drug discovery, have been published in the scientific literature. This review highlights the key events in the history of HTC with emphasis on library design. A historical perspective on the design of screening, targeted, and optimization libraries and their application is presented. Design strategies pioneered in the 1990s remain viable in the twenty-first century.
Collapse
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, Exton, PA, USA.
| |
Collapse
|
17
|
Dolle RE, Bourdonnec BL, Worm K, Morales GA, Thomas CJ, Zhang W. Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009. J Comb Chem 2010; 12:765-806. [PMID: 20923157 PMCID: PMC4140011 DOI: 10.1021/cc100128w] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Roland E Dolle
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | | | |
Collapse
|
18
|
Metzger A, Qin LY, Cole AG, Saionz KW, Brescia MR, Gstach H, Wareing JR, Zimmermann J, Brill WKD, Baldwin JJ, Dolle RE, Henderson I. Combined solution-phase and solid-phase synthesis of 2-amino-7,8-dihydropteridin-6(5H)-ones. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2009.10.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Chu GH, Le Bourdonnec B, Gu M, Ajello CW, Leister LK, Sellitto I, Cassel JA, Tuthill PA, O’ Hare H, DeHaven RN, Dolle RE. Design and Synthesis of Imidazopyrimidine Derivatives as Potent iNOS Dimerization Inhibitors. Open Med Chem J 2009; 3:8-13. [PMID: 19966921 PMCID: PMC2788740 DOI: 10.2174/1874104500903010008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/10/2009] [Revised: 08/19/2009] [Accepted: 08/20/2009] [Indexed: 11/24/2022]
Abstract
A series of imidazopyrimidine derivatives with the general formula I was synthesized and identified as potent inhibitors of iNOS dimer formation, a prerequisite for proper functioning of the enzyme. Stille and Negishi coupling reactions were used as key steps to form the carbon-carbon bond connecting the imidazopyrimidine core to the central cycloalkenyl, cycloalkyl and phenyl ring templates.
Collapse
Affiliation(s)
- Guo-Hua Chu
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Minghua Gu
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Christopher W Ajello
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Lara K Leister
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Ian Sellitto
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Joel A Cassel
- Department of Pharmacology, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Paul A Tuthill
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Heather O’ Hare
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Robert N DeHaven
- Department of Pharmacology, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | - Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| |
Collapse
|
20
|
Barker WM, Worm K, Dolle RE. High-performance liquid chromatographic enantioseparation of methanobenzazocines. J Chromatogr A 2009; 1216:7708-14. [DOI: 10.1016/j.chroma.2009.08.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Revised: 08/06/2009] [Accepted: 08/12/2009] [Indexed: 11/29/2022]
|
21
|
Le Bourdonnec B, Windh RT, Leister LK, Zhou QJ, Ajello CW, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). J Med Chem 2009; 52:5685-702. [PMID: 19694468 DOI: 10.1021/jm900773n] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Selective, nonpeptidic delta opioid receptor agonists have been the subject of great interest as potential novel analgesic agents. The discoveries of BW373U86 (1) and SNC80 (2) contributed to the rapid expansion of research in this field. However, poor drug-like properties and low therapeutic indices have prevented clinical evaluation of these agents. Doses of 1 and 2 similar to those required for analgesic activity produce convulsions in rodents and nonhuman primates. Recently, we described a novel series of potent, selective, and orally bioavailable delta opioid receptor agonists. The lead derivative, ADL5859 (4), is currently in phase II proof-of-concept studies for the management of pain. Further structure activity relationship exploration has led to the discovery of ADL5747 (36), which is approximately 50-fold more potent than 4 in an animal model of inflammatory pain. On the basis of its favorable efficacy, safety, and pharmacokinetic profile, 36 was selected as a clinical candidate for the treatment of pain.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Departments of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Chu GH, Saeui CT, Worm K, Weaver DG, Goodman AJ, Broadrup RL, Cassel JA, DeHaven RN, LaBuda CJ, Koblish M, Brogdon B, Smith S, Bourdonnec BL, Dolle RE. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists. Bioorg Med Chem Lett 2009; 19:5931-5. [DOI: 10.1016/j.bmcl.2009.08.063] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2009] [Revised: 08/13/2009] [Accepted: 08/13/2009] [Indexed: 11/24/2022]
|
23
|
Dolle RE, Bourdonnec BL, Goodman AJ, Morales GA, Thomas CJ, Zhang W. Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2008. ACTA ACUST UNITED AC 2009; 11:739-90. [PMID: 19715292 DOI: 10.1021/cc9000828] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Worm K, Weaver DG, Green RC, Saeui CT, Dulay DMS, Barker WM, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Brogdon BL, Smith SA, Dolle RE. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. Bioorg Med Chem Lett 2009; 19:5004-8. [DOI: 10.1016/j.bmcl.2009.07.057] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Revised: 07/08/2009] [Accepted: 07/09/2009] [Indexed: 01/27/2023]
|
25
|
|
26
|
Goodman AJ, Ajello CW, Worm K, Bourdonnec BL, Savolainen MA, O’Hare H, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE. CB2 selective sulfamoyl benzamides: Optimization of the amide functionality. Bioorg Med Chem Lett 2009; 19:309-13. [DOI: 10.1016/j.bmcl.2008.11.091] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2008] [Revised: 11/21/2008] [Accepted: 11/24/2008] [Indexed: 10/21/2022]
|
27
|
Dolle RE, Bourdonnec BL, Goodman AJ, Morales GA, Thomas CJ, Zhang W. Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2007. ACTA ACUST UNITED AC 2008; 10:753-802. [PMID: 18991466 DOI: 10.1021/cc800119z] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Roland E. Dolle
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Bertrand Le Bourdonnec
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Allan J. Goodman
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Guillermo A. Morales
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Craig J. Thomas
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| | - Wei Zhang
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, Semafore Pharmaceuticals Inc., 8496 Georgetown Road, Indianapolis, Indiana 46268, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, and Department of Chemistry, University of Massachusetts, 100 Morrissey Boulevard, Boston, Massachusetts 02125
| |
Collapse
|
28
|
Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem 2008; 51:5893-6. [PMID: 18788723 DOI: 10.1021/jm8008986] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Selective delta opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable delta agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.
Collapse
|
29
|
Le Bourdonnec B, Barker WM, Belanger S, Wiant DD, Conway-James NC, Cassel JA, O'Neill TJ, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg Med Chem Lett 2008; 18:2006-12. [PMID: 18313920 DOI: 10.1016/j.bmcl.2008.01.106] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2007] [Revised: 01/28/2008] [Accepted: 01/29/2008] [Indexed: 10/22/2022]
Abstract
A series of N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines, mu opioid receptor antagonists, analogs of alvimopan, were prepared using solid phase methodology. This study led to the identification of a highly selective mu opioid receptor antagonist, which interacts selectively with mu peripheral receptors.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Le Bourdonnec B, Leister LK, Ajello CA, Cassel JA, Seida PR, O'Hare H, Gu M, Chu GH, Tuthill PA, DeHaven RN, Dolle RE. Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett 2007; 18:336-43. [PMID: 18024030 DOI: 10.1016/j.bmcl.2007.10.073] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2007] [Revised: 10/19/2007] [Accepted: 10/20/2007] [Indexed: 11/24/2022]
Abstract
Nitric oxide (NO), a mediator of various physiological and pathophysiological processes, is synthesized by three isozymes of nitric oxide synthase (NOS). Potential candidate clinical drugs should be devoid of inhibitory activity against endothelial NOS (eNOS), since eNOS plays an important role in maintaining normal blood pressure and flow. A new series of aminopiperidines as potent inhibitors of iNOS were identified from a HTS lead. From this study, we identified compound 33 as a potent iNOS inhibitor, with >25-fold selectivity over eNOS and 16-fold selectivity over nNOS.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Dolle RE, Le Bourdonnec B, Goodman AJ, Morales GA, Salvino JM, Zhang W. Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2006. ACTA ACUST UNITED AC 2007; 9:855-902. [PMID: 17877417 DOI: 10.1021/cc700111e] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Roland E Dolle
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | | | |
Collapse
|
32
|
Dolle RE, Michaut M, Martinez-Teipel B, Belanger S, Graczyk TM, DeHaven RN. Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett 2007; 17:2656-60. [PMID: 17350835 DOI: 10.1016/j.bmcl.2007.01.092] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2006] [Revised: 01/29/2007] [Accepted: 01/30/2007] [Indexed: 10/23/2022]
Abstract
A series of opioid peptide ligands containing modified N-terminal tyrosine (Tyr) residues was prepared and evaluated against cloned human mu, delta, and kappa opioid receptors. This work extends the recent discovery that (S)-4-carboxamidophenylalanine (Cpa) is an effective tyrosine bioisostere. Amino acids containing negatively charged functional groups in place of tyrosine's phenolic hydroxyl lacked receptor affinity, while exchange of Tyr for (S)-4-aminophenylalanine was modestly successful. Peptides containing the new amino acids, (S)-4-carboxamido-2,6-dimethylphenylalanine (Cdp) and (S)-beta-(2-aminobenzo[d]thiazol-6-yl)alanine (Aba), displayed binding (K(i)) and functional (EC(50)) profiles comparable to the parent ligands at the three receptors. Cdp represents the best performing Tyr surrogate in terms of overall activity, while Cpa and Aba show a subtle proclivity toward the delta receptor.
Collapse
MESH Headings
- Chemistry, Pharmaceutical/methods
- Cloning, Molecular
- Drug Design
- Humans
- Hydrogen Bonding
- Kinetics
- Ligands
- Models, Chemical
- Molecular Conformation
- Peptides/chemistry
- Receptors, Opioid/chemistry
- Receptors, Opioid, delta/chemistry
- Receptors, Opioid, kappa/chemistry
- Receptors, Opioid, mu/chemistry
- Tyrosine/chemistry
Collapse
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | |
Collapse
|
33
|
Chu GH, Gu M, Cassel JA, Belanger S, Graczyk TM, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE. Novel malonamide derivatives as potent κ opioid receptor agonists. Bioorg Med Chem Lett 2007; 17:1951-5. [PMID: 17307360 DOI: 10.1016/j.bmcl.2007.01.053] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2006] [Revised: 01/08/2007] [Accepted: 01/09/2007] [Indexed: 11/16/2022]
Abstract
A novel series of malonamide derivatives was synthesized. These amides were shown to be potent and selective kappa opioid receptor agonists.
Collapse
Affiliation(s)
- Guo-Hua Chu
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Le Bourdonnec B, Goodman AJ, Michaut M, Ye HF, Graczyk TM, Belanger S, Herbertz T, Yap GPA, DeHaven RN, Dolle RE. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists. J Med Chem 2007; 49:7278-89. [PMID: 17149858 DOI: 10.1021/jm060486f] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The series of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines have been widely investigated as opioid receptor antagonists. One of our research goals was to explore the bioactive conformation of the N-phenethyl trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine derivative 3, prototypical mu-opioid antagonist in this series. In this effort, the rotational degrees of freedom of the N-substituent of 3 were limited by incorporation of an ethylene bridge between the piperidine 2- or 6-position of 3 and the benzylic position of the N-phenethyl moiety. The overall modification led to a novel series of fused bicyclic derivatives of the octahydroquinolizine chemical class, conformationally restricted analogue of 3. The constrained analogues 6 and 9 showed high affinity toward the mu-opioid receptor. Compound 6 was found to be a mu-opioid antagonist, whereas the constrained analogue 9 displayed potent mu-agonist activity in vitro. This study provides additional information about the molecular determinants for mu recognition, the structural features affecting ligand binding, and the structure function relationships.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Le Bourdonnec B, Goodman AJ, Graczyk TM, Belanger S, Seida PR, DeHaven RN, Dolle RE. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists. J Med Chem 2007; 49:7290-306. [PMID: 17149859 DOI: 10.1021/jm0604878] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To better understand structural requirements for a mu ligand of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class to interact with the mu opioid receptor, we have described in the previous article (Le Bourdonnec, B. et al. J. Med. Chem. 2006, 25, 7278-7289) new, constrained analogues of the N-phenethyl derivative 3. One of the active constrained analogues, compound 4, exhibited subnanomolar mu-opioid receptor affinity (K(i) = 0.62 nM) and potent mu-opioid antagonist activity (IC(50) = 0.54 nM). On the basis of structure 4, a new series of mu-opioid receptor antagonists were designed. In these compounds the octahydroquinolizine template of 4 was replaced by an octahydro-1H-pyrido[1,2-a]pyrazine scaffold. The new derivatives were tested for their binding affinities and in vitro functional activity against the cloned human mu-, delta-, and kappa-opioid receptors. From this study, we identified compound 36, which displays high affinity toward the mu-opioid receptor (K(i) = 0.47 nM), potent mu in vitro antagonist activity (IC(50) = 1.8 nM) and improved binding selectivity profile mu/kappa and mu/delta, when compared to 4.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Affiliation(s)
- Roland E Dolle
- Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| | | | | | | | | |
Collapse
|
37
|
Le Bourdonnec B, Goodman AJ, Michaut M, Ye HF, Graczyk TM, Belanger S, DeHaven RN, Dolle RE. Synthesis and structure–activity relationships of a new series of 2α-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as μ-selective opioid antagonists. Bioorg Med Chem Lett 2006; 16:864-8. [PMID: 16298525 DOI: 10.1016/j.bmcl.2005.11.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2005] [Revised: 11/02/2005] [Accepted: 11/03/2005] [Indexed: 10/25/2022]
Abstract
Structure-activity relationships at the 2alpha-position of the piperidine ring of the trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine mu-opioid antagonist series were investigated. This study showed that only small linear alkyl groups (methyl, propyl) are tolerated at the 2alpha-position of the piperidine ring of this series.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| |
Collapse
|
39
|
Macleod C, Martinez-Teipel BI, Barker WM, Dolle RE. Annulation of Primary Amines to Piperazines and Diazaspirocycles Utilizing α-Methyl Benzyl Resin. ACTA ACUST UNITED AC 2005; 8:132-40. [PMID: 16398564 DOI: 10.1021/cc050106w] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The microwave-assisted solid-phase synthesis of piperazines, 3,9-diazaspiro[5.5]undecanes and 2,9-diazaspiro[5.5]undecanes is reported. The synthesis relies on the direct annulation of primary amines with resin-bound bismesylates. Critical to the success of this chemistry was the development of alpha-methyl benzyl carbamate resin linker. This resin permits the cleavage of the heterocycles under mildly acidic conditions, free of contaminating linker-derived N-alkylated byproducts.
Collapse
Affiliation(s)
- Calum Macleod
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA
| | | | | | | |
Collapse
|
40
|
Chu GH, Gu M, Cassel JA, Belanger S, Stabley GJ, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE. Novel phenylamino acetamide derivatives as potent and selective kappa opioid receptor agonists. Bioorg Med Chem Lett 2005; 16:645-8. [PMID: 16263278 DOI: 10.1016/j.bmcl.2005.10.034] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2005] [Revised: 10/10/2005] [Accepted: 10/12/2005] [Indexed: 11/15/2022]
Abstract
A novel series of phenylamino acetamide derivatives was synthesized. These amides were shown to be potent and selective kappa opioid receptor agonists.
Collapse
Affiliation(s)
- Guo-Hua Chu
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Chu GH, Gu M, Cassel JA, Belanger S, Graczyk TM, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE. Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints. Bioorg Med Chem Lett 2005; 15:5114-9. [PMID: 16203140 DOI: 10.1016/j.bmcl.2005.08.094] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2005] [Revised: 08/24/2005] [Accepted: 08/24/2005] [Indexed: 11/25/2022]
Abstract
Two novel chemical classes of kappa opioid receptor agonists, chroman-2-carboxamide derivatives and 2,3-dihydrobenzofuran-2-carboxamide derivatives, were synthesized. These agents exhibited high and selective affinity for the kappa opioid receptor.
Collapse
Affiliation(s)
- Guo-Hua Chu
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Dolle RE, MacLeod C, Martinez-Teipel B, Barker W, Seida PR, Herbertz T. Solid/Solution-Phase Annulation Reagents: Single-Step Synthesis of Cyclic Amine Derivatives. Angew Chem Int Ed Engl 2005. [DOI: 10.1002/ange.200501665] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
43
|
Dolle RE, MacLeod C, Martinez-Teipel B, Barker W, Seida PR, Herbertz T. Solid/Solution-Phase Annulation Reagents: Single-Step Synthesis of Cyclic Amine Derivatives. Angew Chem Int Ed Engl 2005; 44:5830-3. [PMID: 16078285 DOI: 10.1002/anie.200501665] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | |
Collapse
|
44
|
Le Bourdonnec B, Ajello CW, Seida PR, Susnow RG, Cassel JA, Belanger S, Stabley GJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett 2005; 15:2647-52. [PMID: 15863335 DOI: 10.1016/j.bmcl.2005.03.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2005] [Revised: 03/03/2005] [Accepted: 03/04/2005] [Indexed: 10/25/2022]
Abstract
Some kappa opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50=26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50>10 microM) while displaying high affinity toward the cloned human kappa opioid receptor, good kappa/delta and kappa/mu selectivity, and potent in vitro and in vivo agonist activity.
Collapse
Affiliation(s)
- Bertrand Le Bourdonnec
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Tuthill PA, Seida PR, Barker W, Cassel JA, Belanger S, DeHaven RN, Koblish M, Gottshall SL, Little PJ, DeHaven-Hudkins DL, Dolle RE. Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists. Bioorg Med Chem Lett 2005; 14:5693-7. [PMID: 15482950 DOI: 10.1016/j.bmcl.2004.08.041] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2004] [Accepted: 08/17/2004] [Indexed: 11/24/2022]
Abstract
A new class of kappa-opioid receptor agonists is described. The design of these agents was based upon energy minimization and structural overlay studies of the generic azepin-2-one structure 3 with the crystal structure of arylacetamide kappa agonist 1, ICI 199441. The most active compound identified was ligand 4a (K(i)=0.34 nM), which demonstrated potent antinociceptive activity after oral administration in rodents.
Collapse
Affiliation(s)
- Paul A Tuthill
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Guo T, Adang AEP, Dolle RE, Dong G, Fitzpatrick D, Geng P, Ho KK, Kultgen SG, Liu R, McDonald E, McGuinness BF, Saionz KW, Valenzano KJ, van Straten NCR, Xie D, Webb ML. Small molecule biaryl FSH receptor agonists. Part 1: Lead discovery via encoded combinatorial synthesis. Bioorg Med Chem Lett 2004; 14:1713-6. [PMID: 15026056 DOI: 10.1016/j.bmcl.2004.01.042] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2003] [Revised: 01/16/2004] [Accepted: 01/19/2004] [Indexed: 10/26/2022]
Abstract
High-throughput screening of two million compounds in 37 distinct encoded combinatorial libraries using FSH receptor transfected cells provided small molecule agonists such as 1 (EC(50)=3 microM) and 2 (EC(50)=3.9 microM), based on which a focused combinatorial library with a total of 31372 compounds was designed, synthesized, and screened to reveal 72 novel biaryl FSH receptor agonists such as 8a-c as well as a unique combinatorial SAR.
Collapse
Affiliation(s)
- Tao Guo
- Pharmacopeia, Inc, PO Box 5350, Princeton, NJ 08543-5350,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Mediation of antinociception via opioid receptors located in the periphery is a viable strategy to produce analgesia without the occurrence of side effects associated with stimulation of opioid receptors located in the central nervous system. Peripheral opioid receptors are particularly important in inflammatory pain states and in the responses to pruritogenic stimuli, and have been implicated in the transmission of visceral pain. Medicinal chemistry approaches to achieve peripheralization of opioid agonists have started with a centrally acting opioid agonist as a template, and introduced features of lipophilicity, hydrophilicity, or combined lipophilicity and hydrophilicity to achieve amphiphilicity. Quaternarization of centrally acting opioid agonists or identification of compounds that serve as substrates for the mdr transporter to achieve transport out of the brain has also been employed. The in vivo assays used to identify peripherally selective compounds have measured a variety of behavioral and pharmacokinetic endpoints, with varying degrees of predictability. This review focuses on a discussion of these methods, as well as a review of those compounds where sufficient data exist to support a claim of peripheralization in vivo.
Collapse
MESH Headings
- Analgesics, Opioid/chemical synthesis
- Analgesics, Opioid/pharmacokinetics
- Analgesics, Opioid/pharmacology
- Animals
- Drug Design
- Humans
- Molecular Conformation
- Pain Measurement/drug effects
- Peripheral Nerves/drug effects
- Receptors, Opioid/agonists
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/chemistry
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, kappa/chemistry
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/chemistry
- Structure-Activity Relationship
Collapse
|
48
|
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA.
| |
Collapse
|
49
|
Dolle RE, Machaut M, Martinez-Teipel B, Belanger S, Cassel JA, Stabley GJ, Graczyk TM, DeHaven RN. (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. Bioorg Med Chem Lett 2004; 14:3545-8. [PMID: 15177470 DOI: 10.1016/j.bmcl.2004.04.039] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2004] [Revised: 04/12/2004] [Accepted: 04/12/2004] [Indexed: 11/20/2022]
Abstract
(S)-4-(Carboxamido)phenylalanine (Cpa) is examined as a bioisosteric replacement for the terminal tyrosine (Tyr) residue in a variety of known peptide ligands for the mu, delta and kappa opioid receptors. The Cpa-containing peptides, assayed against cloned human opioid receptors, display comparable binding affinity (Ki), and agonist potency (EC50) to the parent ligands at the three receptors. Cpa analogs of delta selective peptides show an increase in delta selectivity relative to the mu receptor. Cpa is the first example of an amino acid that acts as a surrogate for Tyr in opioid peptide ligands, challenging the long-standing belief that a phenolic residue is required for high affinity binding.
Collapse
MESH Headings
- Amino Acids, Aromatic/chemical synthesis
- Amino Acids, Aromatic/pharmacology
- Analgesics, Opioid/chemical synthesis
- Analgesics, Opioid/pharmacology
- Binding Sites
- Cell Line
- Humans
- Ligands
- Molecular Structure
- Opioid Peptides/metabolism
- Phenol/chemistry
- Phenylalanine/analogs & derivatives
- Phenylalanine/chemical synthesis
- Phenylalanine/pharmacology
- Receptors, Opioid, delta/drug effects
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/drug effects
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/drug effects
- Receptors, Opioid, mu/metabolism
- Tyrosine/pharmacology
Collapse
Affiliation(s)
- Roland E Dolle
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Zhou QJ, Worm K, Dolle RE. 10-Hydroxy-10,9-boroxarophenanthrenes: Versatile Synthetic Intermediates to 3,4-Benzocoumarins and Triaryls. J Org Chem 2004; 69:5147-9. [PMID: 15255755 DOI: 10.1021/jo049343w] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
10-Hydroxy-10,9-boroxarophenanthrenes were obtained as unexpected major products upon BBr(3)-mediated O-demethylation of 2-methoxybiaryls. The formation likely proceeds via intramolecular electrophilic aromatic cyclization of a reactive dibromoaryloxyborane intermediate. Essentially quantitative yields of 10-hydroxy-10,9-boroxarophenanthrenes were also obtained from 2-hydroxybiaryl and BCl(3)/AlCl(3) with use of a modified literature procedure. As synthetic intermediates, 10-hydroxy-10,9-boroxarophenanthrenes were efficiently converted to 3,4-benzocoumarins and triaryls through Pd-catalyzed CO insertion and Suzuki reaction.
Collapse
Affiliation(s)
- Q Jean Zhou
- Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341-1127, USA.
| | | | | |
Collapse
|